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Introduction
Allergic asthma typically exhibits a T helper cell type 2 (Th2) inflammatory response and airway hyperres-
ponsiveness (AHR) (1). A common aeroallergen, house dust mite (HDM), affects approximately 50%–85% of  
patients with asthma (2–4). Because of its complex nature, HDM likely activates several pattern recognition 
receptors and elicits a mixed inflammatory response, mucus metaplasia, and AHR (4). We have demonstrated 
that HDM challenge induces ER stress in the lung, thereby activating the unfolded protein response (UPR), 
which is associated with many hallmarks of allergic airway disease in humans and rodents (5–8). The UPR is 
an adaptive response consisting of  the activation of  transducers protein kinase R–like ER kinase (PERK), 
Conjugated bile acids (CBAs), such as tauroursodeoxycholic acid (TUDCA), are known to resolve 
the inflammatory and unfolded protein response (UPR) in inflammatory diseases, such as 
asthma. Whether CBAs exert their beneficial effects on allergic airway responses via 1 arm or 
several arms of the UPR, or alternatively through the signaling pathways for conserved bile 
acid receptor, remains largely unknown. We used a house dust mite–induced (HDM-induced) 
murine model of asthma to evaluate and compare the effects of 5 CBAs and 1 unconjugated 
bile acid in attenuating allergen-induced UPR and airway responses. Expression of UPR-
associated transcripts was assessed in airway brushings from human patients with asthma and 
healthy subjects. Here we show that CBAs, such as alanyl β-muricholic acid (AβM) and TUDCA, 
significantly decreased inflammatory, immune, and cytokine responses; mucus metaplasia; and 
airway hyperresponsiveness, as compared with other CBAs in a model of allergic airway disease. 
CBAs predominantly bind to activating transcription factor 6α (ATF6α) compared with the other 
canonical transducers of the UPR, subsequently decreasing allergen-induced UPR activation and 
resolving allergic airway disease, without significant activation of the bile acid receptors. TUDCA 
and AβM also attenuated other HDM-induced ER stress markers in the lungs of allergic mice. 
Quantitative mRNA analysis of airway epithelial brushings from human subjects demonstrated 
that several ATF6α-related transcripts were significantly upregulated in patients with asthma 
compared with healthy subjects. Collectively, these results demonstrate that CBA-based therapy 
potently inhibits the allergen-induced UPR and allergic airway disease in mice via preferential 
binding of the canonical transducer of the UPR, ATF6α. These results potentially suggest a novel 
avenue to treat allergic asthma using select CBAs.
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inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6α (ATF6α) (9). These pathways 
coordinate to suppress protein production, boost the ER-associated degradation machinery, and increase chap-
erones, members of the protein disulfide isomerase (PDI) family, and antioxidant enzymes that ensure proper 
protein folding (10, 11). These combined responses help maintain ER homeostasis and therefore cell survival. 
However, prolonged and chronic activation of the UPR may induce cellular apoptosis and has been implicated 
in the pathogenesis of inflammatory and fibrotic diseases (12–15).
The crucial role that the UPR plays in chronic airway disorders highlights its potential as a target for 
novel therapies in diseases such as asthma (6, 16). Our group and others have demonstrated the therapeutic 
potential of  the conjugated bile acid (CBA) tauroursodeoxycholic acid (TUDCA) in relieving ER stress 
and airway inflammatory responses (7, 17, 18). CBAs such as TUDCA are generally well tolerated and 
have shown positive effects in clinical trials for UPR-related diseases, such as primary biliary cholangitis, 
amyloidosis, and amyotrophic lateral sclerosis (19–21). Moreover, because different arms of  the UPR and 
their regulated genes have been implicated in various cell types in the inflamed lung, including CHOP in 
macrophages; IRE1β, PDIA3, and ATF6α in airway epithelial cells; and X-box–binding protein 1 (XBP1) 
in eosinophils and neutrophils (6, 22–26), it has become clear that therapeutic agents targeting multiple 
components of  the UPR could be more effective at inhibiting allergen-induced airway responses. Whereas 
CBAs such as TUDCA are established attenuators of  the UPR, there are no studies that specifically address 
the mechanisms of  action of  CBAs in inhibiting the allergen-induced UPR in the lungs.
The objectives of  this study were to evaluate the therapeutic potential of  5 CBAs and 1 unconjugated 
bile acid and their putative mechanisms of  action in inhibiting the allergen-induced UPR and subsequent 
airway responses. Altogether, the study characterizes additional CBAs as effective attenuators of  allergic 
airway disease via direct interaction with transducers of  the UPR and implicates ATF6α in the resolution 
of  airway inflammation. Furthermore, we report that ATF6α-related genes are upregulated in human asth-
matic epithelial cells, suggesting a novel target to control allergic airway disease in humans.
Results
TUDCA attenuates inflammation and ER stress in a murine model of  allergic asthma. We previously reported that 
the CBA TUDCA potently attenuates hallmarks of  allergic airway disease in C57BL/6J mice (7). The first 
aim of  the current study was to determine whether TUDCA could similarly attenuate pathology in a strain 
of  mouse more strongly skewed toward the Th2 immune response typically associated with allergic airway 
disease (27). Here, we used our established therapeutic regimen of  intranasal HDM and oropharyngeal 
TUDCA administration in the BALB/cJ strain of  mouse (28, 29) (Figure 1A). With the exception of  mac-
rophages, HDM-induced increases in total airway inflammatory cell numbers, eosinophils, neutrophils, and 
lymphocytes were significantly decreased in TUDCA-treated mice (Figure 1, B–F). Increased levels of  the 
inflammatory cytokines IL-6 and IL-33 and the chemokines C-C motif  chemokine ligand 11 (CCL11/eotax-
in-1), CCL20/macrophage inflammatory protein 3α (MIP3α), and CXCL1/keratinocyte-derived chemokine 
(KC), measured in lung homogenates of  allergic mice, were similarly attenuated by TUDCA (Figure 1, 
G–K). Western blot analysis and densitometry confirmed the decrease of  UPR markers glucose-regulated 
protein 94 (GRP94), GRP78, subunit 50 of  ATF6α (ATF6α50), PDIA5, PDIA3, and CCAAT/enhancer 
binding protein homologous protein (CHOP) (Figure 1L and Supplemental Figure 1, densitometry; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.98101DS1) in 
HDM-challenged, TUDCA-treated BALB/cJ mice.
TUDCA attenuates HDM-induced AHR, several innate/adaptive immune cytokine responses, and mucus-re-
lated markers associated with murine allergic asthma. TUDCA administration to HDM-treated mice atten-
uated HDM-induced Newtonian resistance (Rn) but not tissue resistance/damping (G) and tissue stiff-
ness/elastance (H) at the highest concentration(s) of  methacholine (Figure 2, A–C, and Supplemental 
Figure 2). Moreover, levels of  cytokines IL-4, IL-5, and IL-13, as well as IL-17A, were elevated in 
the lungs of  HDM-treated compared with PBS-treated control mice (Figure 2, D–G). IFN-γ was not 
detected in any of  the samples. With TUDCA, allergic mice produced significantly less IL-4, IL-5, and 
IL-13, but there was no significant decrease in IL-17A, as compared with untreated allergic mice. Treat-
ment with TUDCA also significantly attenuated levels of  HDM-induced IgE in the serum (Figure 2H). 
Although administration of  TUDCA did not decrease HDM-induced expression of  the mucin-related 
genes Muc5ac and Clca1 (Figure 2, I and J), TUDCA treatment significantly reduced mucus metaplasia, 
as quantified by cells from the lungs stained with periodic acid–Schiff  (PAS) (Figure 2, K and L).
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Effects of  other CBAs on allergen-induced inflammation and the UPR in a murine model of  allergic asth-
ma. Considering the ability of  TUDCA to alleviate allergic airway responses, we decided to evaluate 
the efficacy of  additional CBAs not previously tested in an allergic model of  asthma. These include 
4 CBAs: taurochenocholic acid (TCCA), glycyl β-muricholic acid (GβM), alanyl β-muricholic acid 
(AβM), and glycyl-nor-β-muricholic acid (GnβM), along with the unconjugated bile acid (UBA) β-muri-
cholic acid (βM) (Figure 3A). We used our established therapeutic regimen of  intranasal HDM (or PBS 
vehicle) exposure combined with oropharyngeal instillation of  CBAs/UBA (or DMSO vehicle) (Figure 
3B). Total inflammatory cell numbers, eosinophils, neutrophils, and lymphocytes were all significant-
ly increased in HDM mice treated with vehicle control (HDM plus DMSO) compared with control 
mice that received PBS plus DMSO (Figure 3, C–G). Only AβM was effective at significantly reducing 
HDM-induced total inflammatory cell numbers, eosinophils, neutrophils, and lymphocytes. TCCA sig-
nificantly decreased airway neutrophilia; however, no other CBA/UBA–treated groups showed signifi-
cant reductions in inflammatory cell numbers (Figure 3, C–G). Analysis of  the cytokines IL-6 and IL-33 
and chemokines CCL11, CCL20, and CXCL1 showed that they were significantly elevated in the lungs 
of  HDM plus DMSO compared with PBS plus DMSO mice (Figure 4, A–E). However, AβM was the 
only CBA that significantly reduced levels of  IL-6, IL-33, CCL11, CXCL1, and CCL20 (Figure 4, A–E).
Based on these results, we focused our attention on comparing the expression of  several UPR mark-
ers by Western blotting in TCCA- and AβM-treated lung samples with those from PBS plus DMSO and 
HDM plus DMSO controls. Compared with PBS plus DMSO mice, lungs from HDM plus DMSO mice 
showed significant increases in all measured UPR markers (Figure 4F, Supplemental Figure 3, densitom-
etry). The AβM (HDM plus AβM) group displayed significantly decreased GRP94, GRP78, ATF6α50, 
PDIA5, and CHOP in comparison with the HDM plus DMSO or HDM plus TCCA groups (Figure 4F 
and Supplemental Figure 3, densitometry).
We next examined the effectiveness of  CBAs/UBA on AHR, several innate/adaptive immune cyto-
kine responses, and mucus-related markers associated with asthma. We determined that the HDM plus 
Figure 1. TUDCA attenuates allergic airway inflammation and the UPR. (A) HDM and TUDCA challenge and treatment regimen. (B–F) Inflammation 
quantified from the BAL. n = 10 mice/group from 2 experiments (outliers removed in various groups; total cells PBS: n = 1; eosinophils PBS: n = 1; neu-
trophils PBS: n = 2; TUDCA: n = 2; macrophages PBS: n = 1; lymphocytes PBS: n = 2). (G–K) Quantification of cytokines/chemokines by ELISA from lung 
homogenates. n = 10 mice/group from 2 experiments. Kruskal-Wallis, 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. Two com-
parisons, both with the HDM group. *P < 0.05 vs. PBS group; #P < 0.05 vs. HDM group; ns, not significant. Error bars represent ± SEM. (L) Expression of 
ER stress markers by Western blot analysis of lung homogenates of HDM-sensitized and -challenged mice treated with TUDCA. n = 4 representative 
lung lysates for each group for the Western blots. Densitometry in Supplemental Figure 1. ns, not significant. Error bars represent ± SEM.
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DMSO group significantly increased all 3 measured AHR parameters (i.e., Rn, G, and H). The only 
compound examined that effectively decreased HDM-induced Rn and G was βM (Figure 5, A and B, 
and Supplemental Figure 4). In contrast, HDM-induced increases in Rn, G, and H were not significant-
ly reduced by GβM, AβM, or GnβM (Figure 5, A–C, and Supplemental Figure 4) at the highest dose of  
methacholine (50 mg/ml). The AHR data obtained for TCCA were omitted because of  noncompliance 
for the majority of  the mice according to our cutoff  COD threshold values (see Methods). HDM-in-
duced production of  IL-4 and IL-13 was significantly reduced by AβM, whereas IL-5 and IL-17A were 
not significantly decreased in any groups (Figure 5, D–G). HDM sensitization and challenge also sig-
nificantly increased serum IgE levels, and AβM was able to attenuate the HDM-induced IgE as com-
pared with HDM plus DMSO and other CBA/UBA–treated groups (Figure 5H).
None of  the additional 4 CBAs and 1 UBA were particularly effective at reducing mucus-related read-
outs in BALB/cJ mice. Transcript levels of  Muc5ac and Clca1 in the lungs of  CBA-treated mice did not 
differ from their respective HDM controls (Supplemental Figure 4, D and E). Similarly, PAS staining of  
mucus glycoproteins in the lungs of  CBA-treated mice did not differ from staining of  their respective con-
trols (Supplemental Figure 4, F and G).
Tables 1 and 2 summarize data on the effects of CBAs/UBA (TCCA, βM, GβM, AβM, GnβM, and TUD-
CA) on parameters of allergic airway disease that were measured in our HDM model with BALB/cJ mice. 
AβM and TUDCA had the broadest effects, significantly inhibiting (P < 0.05) 15 and 12 of the 21 measured 
parameters of allergic airway disease, respectively, as compared with their equivalent HDM plus vehicle groups.
CBAs do not activate bile acid receptor signaling. Our next aim was to understand the mechanism whereby 
CBAs attenuate the UPR and allergic airway responses. We began by investigating the effects of  CBAs 
on canonical bile acid receptors farnesoid X receptor (FXR) and G protein–coupled bile acid receptor 1 
Figure 2. TUDCA attenuates AHR, IL-4, IL-5, IL-13, IgE production, and mucus metaplasia. (A–C) AHR by FlexiVent in response to increasing concen-
trations of methacholine (PBS n = 11; HDM n = 16; and HDM plus TUDCA n = 7 mice from 2 experiments). One-way ANOVA, Tukey’s post hoc test. *P < 
0.05 vs. PBS group; #P < 0.05 vs. HDM group (mice were removed in Rn, G, and H; in HDM plus TUDCA group n = 2 based on noncompliance with coeffi-
cient of determination [COD] value). (D–H) Quantification of cytokines by ELISA from lung homogenates and IgE from serum; n = 10 mice/group from 2 
experiments (outliers removed in IL-5; PBS: n = 1). (I and J) Muc5ac and Clca1 expression in the lungs assessed by reverse transcription quantitative PCR 
(RT-qPCR); n = 7 mice from 2 experiments. (K) Representative images of PAS-stained lungs. Scale bar: 25 μm. (L) Quantification of PAS-stained lungs; n = 
3–7 representative mice from 2 experiments. (D–H and J) Kruskal-Wallis, 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. Two compar-
isons, both with the HDM group. *P < 0.05 vs. PBS group; #P < 0.05 vs. HDM group. Rn, Newtonian resistance; G, tissue damping; H, tissue elastance; ns, 
not significant vs. HDM plus PBS group. Error bars represent ± SEM.
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(Takeda G protein–coupled receptor 5, TGR5) and their reported downstream mediators (Figure 6A and 
refs. 30, 31), which are increased by bile acid stimulation in various tissues (e.g., liver and kidney) (32, 33). 
We found that lung transcript levels of  Gpbar1 (TGR5) and downstream mediators Nos3 and Dio2, as well 
as transcript levels of  Nr1h4 (FXR) and downstream mediators Abcb4, Abcc2, and Nr0b2, were not elevated 
in HDM plus TUDCA–treated mice compared with both the PBS and HDM control groups (Figure 6B). 
Interestingly, transcripts of  Nos3 were significantly decreased in both HDM and HDM plus TUDCA mice 
compared with PBS control mice, and transcripts for both Abcc2 and Nr0b2 were significantly decreased 
in HDM plus TUDCA compared with both PBS and HDM groups, suggesting partial inhibition rather 
than activation of  both pathways (Figure 6B). Similarly, lung transcript levels of  Gpbar1, Nr1h4, and their 
downstream mediators did not increase in any of  the other CBA/UBA–treated mouse groups compared 
with the PBS plus DMSO and HDM plus DMSO groups (Figure 7, A–G). Transcript levels of  Nos3 were 
significantly decreased in all HDM-sensitized (CBA-treated and untreated) groups when compared with 
the PBS plus DMSO group (Figure 7C), indicating a potential allergen-specific inhibitory effect on Nos3 
expression in our models. Additionally, transcripts of  Abcc2 were also significantly decreased in the HDM 
plus DMSO group as compared with PBS plus DMSO (Figure 7F). Therefore, the data suggest that the 
primary mechanism by which the 5 CBAs and 1 UBA inhibit allergic airway responses is unlikely to be via 
direct activation of  the classical bile acid receptors.
To further explore whether canonical signaling of  the bile acid receptors is the primary CBA signaling 
mechanism in the lungs, we focused on the 2 CBAs with the broadest effects (Tables 1 and 2). TUDCA and 
AβM, as well as INT-747 and INT-777, which are potent agonists of  FXR and TGR5, respectively (34, 35), 
were all prepared in PBS with DMSO as a vehicle and oropharyngeally instilled without allergen (Figure 
8A). Our results showed that direct oropharyngeal administration of  CBAs or pharmacological agonists do 
not activate the bile acid receptor signaling pathways in the lungs (Figure 8B). Bile acid receptor agonists 
INT-747 and INT-777 failed to increase expression of  several downstream mediators of  FXR and TGR5 
in the lungs, with the exception of  INT-777, which elevated Nrob2 and induced phosphorylation of  PKA 
(Figure 8, B–D). These results suggest that even the pharmacological agonists do not robustly upregulate 
the downstream pathways of  FXR and TGR5 in the lungs.
Figure 3. CBAs attenuate HDM-induced airway inflammation. (A) Structures of the CBAs and UBA. (B) HDM and CBA treatment protocol. (C–G) Inflamma-
tory cells quantified from the BAL, PBS, and HDM plus DMSO n = 6 mice/group from 2 experiments; HDM plus TCCA/βM/GM/AβM/GnβM n = 10 mice/group 
from 2 experiments (outliers removed in various groups; eosinophils PBS: n = 1; βM: n = 1; AM: n = 1. PMNs: TCCA: n = 2; AβM: n = 1. Macrophages: βM: n = 1; 
GβM: n = 1. Lymphocytes: βM: n = 1). *P < 0.05 vs. PBS plus DMSO group; #P < 0.05 vs. HDM plus DMSO group. ns, not significant. Error bars represent ± SEM.
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CBAs directly bind canonical transducers of  the UPR. Because CBAs did not activate FXR or TGR5 
(Figures 7 and 8), but select CBAs inhibited HDM-induced markers of  the UPR (Figure 1L and Figure 
4F), we hypothesized that select CBAs attenuate the UPR and allergic airway responses by inhibiting 
1 or more of  the transducers of  UPR signaling, namely ATF6α, PERK, or IRE1α. First, we modified 
an existing bile acid assay to address whether CBAs bind directly to these UPR transducers (Figure 
9A). Briefly, CBA-treated or untreated cell lysates were mixed with antibodies against ATF6α, PERK, 
or IRE1α; washed of  excess unbound CBAs; and pulled down, and then we quantified protein-bound 
CBAs using a bile acid colorimetric assay.
Initially, we applied our modified bile acid assay to cell lysates from human bronchial epithelial 
(HBE) cells treated with TUDCA or with PBS as a control (Figure 9B). The assay showed TUDCA 
was bound to all 3 transducers, with increased binding of  ATF6α over PERK and IRE1α. We then 
applied this modified bile acid assay to lung lysates prepared from HDM-sensitized and -challenged 
mice treated with CBAs or UBA. ATF6α- or IRE1α-immunoprecipitated samples from lungs of  CBA/
UBA–treated mice had significantly greater ATF6α-bound TUDCA and AβM than untreated PBS 
and HDM controls (Figure 9C). In addition, there was more TUDCA-bound than AβM-bound IRE1α 
recovered from the lungs (Figure 9D), despite no variations in immunoprecipitation of  ATF6α or 
IRE1α from the lung lysates (Figure 9E). Inexplicably, we failed to immunoprecipitate PERK from 
the mouse lung lysates. Furthermore, upon immunoprecipitation of  ATF6α in the presence of  the 
UPR-inducing agent, tunicamycin (Tm), the TUDCA- and AβM-treated HBE cells also showed great-
er recovery of  TUDCA and AβM, while significantly more TUDCA was recovered compared with 
AβM (Figure 9F). We also observed decreases in the Tm-induced UPR in HBE cells treated with 
TUDCA and AβM (Figure 9G). Collectively, these results suggest that TUDCA and AβM are exerting 
their anti–airway allergen effects via binding to the UPR transducers in our allergen-induced model of  
asthma and have direct effects on airway epithelial cells in culture.
UPR markers are increased in asthmatic airway brushings. Finally, we analyzed the expression of UPR-related 
transcripts, with a focus on genes related to ATF6α, in airway epithelial brushings from healthy human and asth-
matic subjects (Supplemental Table 1), as previously described (36, 37). Patients with asthma showed significant 
increases in transcripts for HSPA5, PDIA4, PDIA5, PDIA6, RABAC1, EDEM, COPE, and TXN (38–42) (Figure 
10A). Expression of both PDIA5 and RABAC1 in patients with asthma correlated with high blood eosinophils 
(Figure 10B), impaired reversibility upon bronchodilator treatment (Figure 10C), and hyperresponsiveness to 
Figure 4. CBAs attenuate HDM-induced inflammatory cytokines, chemokines, and the UPR. (A–E) Quantification of cytokines/chemokines by ELISAs 
from lung homogenates. Kruskal-Wallis, 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. Six comparisons, all with the HDM plus 
DMSO group. *P < 0.05 vs. PBS plus DMSO group; #P < 0.05 vs. HDM plus DMSO group; ns, not significant. PBS and HDM plus DMSO n = 6 mice/group 
from 2 experiments; HDM plus TCCA/βM/GM/AβM/GnβM n = 10 mice/group from 2 experiments. (F) Expression of UPR markers from lung homogenates 
of HDM-sensitized and -challenged mice treated with AβM, TCCA, or DMSO (vehicle); n = 4 representative lung lysates for each group. Densitometry in 
Supplemental Figure 3. ns, not significant. Error bars represent ± SEM.
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methacholine challenge (PC20, Table 3). The ATF6α-related genes COPE, CREB3, ORMDL3, and TXN simi-
larly correlated with at least 1 pathological feature of asthma, whereas ERP44 and XBP1 were associated with 
reduced asthma pathology in our analyses (Table 3). Collectively, our results from human subjects and animal 
models suggest that patients with asthma upregulate the UPR markers associated with the ATF6α pathway. 
Furthermore, treatment with CBAs, such as TUDCA and AβM, may have the potential to decrease allergen-in-
duced ATF6α activation and subsequent inflammatory and bronchodilator responses.
Discussion
We explored the potential of  5 CBAs and a UBA in alleviating allergen-induced UPR and airway 
responses in an HDM-induced murine model of  allergic asthma. We determined that the CBAs and 
UBA vary in their ability to inhibit allergic airway disease, with AβM and TUDCA imparting the 
broadest effects. CBA-regulated inhibition of  disease was associated with an attenuated UPR, through 
a decrease in ATF6α50. Moreover, our experiments demonstrated direct binding of  CBAs to ATF6α 
without activating downstream bile acid receptor signaling. Finally, ATF6α-dependent and -activating 
transcripts were upregulated in asthmatic airways, and the expression correlated with clinical markers 
of  disease. Taken together, our findings suggest a potentially novel mechanism whereby CBAs inhibit 
allergic airway responses via suppression of  the UPR.
Figure 5. CBAs attenuate HDM-induced AHR, IL-4, IL-5, IL-13, and IgE production. (A–C) AHR measurement by FlexiVent in response to 50 mg/ml metha-
choline. One-way ANOVA and Tukey’s post hoc test for Rn and Kruskal-Wallis and 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutiel 
post hoc test for G and H. *P < 0.05 vs. PBS plus DMSO mice; #P < 0.05 vs. HDM plus DMSO mice. PBS plus DMSO n = 10; HDM plus DMSO n = 13; and βM/
GM/AβM/GnβM plus HDM n = 7 from 2 experiments (mice were removed based on noncompliance with COD value in Rn/G/H βM: n = 1; AβM: n = 1). (D–H) 
Quantification of cytokines by ELISA from lung homogenates and IgE from serum. PBS and HDM plus DMSO n = 6 mice/group from 2 experiments; HDM 
plus TCCA/βM/GβM/AM/GnβM n = 10 mice/group from 2 experiments (outliers removed in various groups; IL-4: PBS plus DMSO n = 1; IL-5: HDM plus DMSO 
n = 1). Kruskal-Wallis, 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. Six comparisons, all with the HDM plus DMSO group. *P < 0.05 
vs. PBS plus DMSO group; #P < 0.05 vs. HDM plus DMSO group; ns, not significant. Error bars represent ± SEM.
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Bile acids are known to regulate cholesterol homeostasis and facilitate digestion and absorption of lipids 
(43). Early studies reported the therapeutic benefits of bile acids in various diseases through the regulation of  
distinct signaling pathways, including the UPR (43–45). We previously reported that TUDCA administration 
in HDM-allergic C57BL/6J mice decreased the UPR, AHR, mucus metaplasia, and airway fibrosis (7). How-
ever, the mechanism through which TUDCA reduced allergic airway disease was not directly addressed. Our 
current study showed that the CBAs AβM and TUDCA are potent inhibitors of the majority of our measured 
parameters of allergic airway disease, this time using the prototypic Th2-predisposed BALB/cJ mouse strain 
(Tables 1 And 2). Collectively, these results demonstrate the beneficial effects of CBAs in 2 strains of mice.
The 5 newly tested CBAs and 1 UBA — TCCA, βM, GβM, AβM, and GnβM — were originally dis-
solved in DMSO and then further diluted in PBS before instillation, unlike TUDCA, which easily dis-
solved in PBS alone. We therefore kept the TUDCA results separate from the other CBAs. HDM-sensi-
tized and -challenged mice treated with the DMSO-dissolved CBAs showed significant improvement in 
many parameters of  allergic airway disease, including AHR. TUDCA and βM significantly diminished 
airway resistance (Rn). βM also significantly inhibited peripheral tissue resistance (G) at the highest 
concentration of  methacholine (Figure 5, A and B). TCCA-treated mice did not yield reliable AHR 
data for reasons currently unknown. Therefore, the TCCA group was excluded from this analysis. It 
should be noted that AβM decreased many of  the measured parameters, without any significant effect 
on AHR or mucus metaplasia. On the other hand, βM decreased AHR and neutrophilia without affect-
ing any other parameters. This dichotomy in AHR and inflammatory response shows that these com-
pounds may be acting on different (UPR) pathways that are independent of  each other. However, addi-
tional detailed experiments are required to substantiate this speculation.
Table 1. HDM plus TUDCA compared with the HDM plus PBS group
Original figure Parameters TUDCA
Airway inflammation
Figure 1B Total cells P = 0.0004
Figure 1C Eosinophils P = 0.0084
Figure 1D Neutrophils P < 0.0001
Figure 1E Macrophages ns
Figure 1F Lymphocytes P = 0.0144
Chemokines/Cytokines
Figure 1G IL-6 P = 0.0151
Figure 1H IL-33 P = 0.0035
Figure 1I CCL11 P = 0.0025
Figure 1J CCL20 P < 0.0001
Figure 1K CXCL1 P < 0.0001
Figure 2D IL-4 P = 0.0020
Figure 2E IL-5 P = 0.0026
Figure 2F IL-13 P < 0.0001
Figure 2G IL-17A ns
Figure 2H IgE P < 0.0001
AHR (% change at 50 mg/ml methacholine dose)
Figure 2A Newtonian resistance (Rn) P = 0.0360
Figure 2B Tissue damping (G) ns
Figure 2C Tissue elastance (H) ns
Mucus
Figure 2I Muc5ac ns
Figure 2J Clca1 ns
Figure 2L PAS P = 0.0405
Summary of TUDCA effects in attenuating measured parameters of allergic airway disease. Total parameters with 
P < 0.05: 15 of 21. Percentage of parameters with P < 0.05 (rounded to nearest absolute value): 71%. Summary of 21 
measured parameters of allergic airway disease presented in previous figures that compare TUDCA plus HDM–treated 
group to their HDM plus PBS group. Post hoc P values in the table are for parameters that were significantly different 
from HDM plus PBS group. ns, not significant compared with HDM plus PBS.
 
9insight.jci.org   https://doi.org/10.1172/jci.insight.98101
R E S E A R C H  A R T I C L E
Recent publications have identified specific CBAs as alleviating and exacerbating inflammatory and 
metabolic diseases via activation of  the bile acid receptors FXR or TGR5 (46–49). Depending on the dis-
ease and the bile acid type, these studies showed that activation of  bile acid receptors leads to either activa-
tion or inhibition of  the NLR family pyrin domain containing 3 inflammasome, which promotes or inhibits 
inflammation, respectively. However, the mechanism of  action of  the specific CBAs used in this study and 
whether the mechanism differs in the setting of  the lungs, an organ not normally exposed to high concen-
trations of  bile acids, has not been explored. In our murine model of  allergic airway disease, expression 
of  transcripts downstream of  FXR and TGR5 were not upregulated in the lungs of  mice treated with any 
of  the 5 CBAs or 1 UBA tested, suggesting that the primary mechanism by which CBAs attenuate allergic 
airway responses may not be through classical bile acid receptor signaling.
We made an effort to elaborate our findings concerning the mechanism of  action of  CBAs in the 
lungs by direct administration of  the CBAs, TUDCA, and AβM, as well as the FXR-specific agonist 
INT-747 and TGR5-specific agonist INT-777, into the airways without allergen. Twenty-four hours 
after administration, expression of  downstream mediators of  the FXR and TGR5 pathways were not 
upregulated in the lungs of  mice instilled with CBAs or agonists. These results suggest that CBAs 
and FXR- and TGR5-specific agonists are unable to activate downstream pathways in the lungs at 
the administered concentrations. There is evidence in the literature of  bile acid activity that is FXR 
Table 2. HDM plus TCCA/βM/GβM/AβM/GnβM compared with the HDM plus DMSO group
Original figure Parameters TCCA βM GβM AβM GnβM
Airway inflammation
Figure 3C Total cells ns ns ns P = 0.0005 ns
Figure 3D Eosinophils ns ns ns P = 0.0027 ns
Figure 3E Neutrophils P = 0.045 ns ns P < 0.0001 ns
Figure 3F Macrophages ns ns ns ns ns
Figure 3G Lymphocytes ns ns ns P = 0.0043 ns
Chemokines/Cytokines
Figure 4A IL-6 ns ns ns P = 0.004 ns
Figure 4B IL-33 ns ns ns P < 0.0001 ns
Figure 4C CCL11 ns ns ns P < 0.0001 ns
Figure 4D CCL20 ns ns ns P < 0.0001 ns
Figure 4E CXCL1 ns ns ns P = 0.0002 ns
Figure 5D IL-4 ns ns ns P = 0.0082 ns
Figure 5E IL-5 ns ns ns ns ns
Figure 5F IL-13 ns ns ns P < 0.0001 ns
Figure 5G IL-17A ns ns ns ns ns
Figure 5H IgE ns ns ns P = 0.0002 ns
AHR (% change at 50 mg/ml methacholine)
Figure 5A Newtonian 
resistance (Rn)
nd P = 0.0093 ns ns ns
Figure 5B Tissue damping (G) nd P = 0.0060 ns ns ns
Figure 5C Tissue elastance (H) nd ns ns ns ns
Mucus
Fig. S4D Muc5ac ns ns ns ns ns
Fig. S4E Clca1 ns ns ns ns ns
Fig. S4G PAS ns ns ns ns ns
Total parameters  
P < 0.05
1 (21) 2 (21) 0 (21) 12 (21) 0 (21)
% of parameters 
P < 0.05 (nearest 
absolute)
5% 10% 0% 57% 0%
AβM has the broadest effects in attenuating measured parameters of allergic airway disease. Summary of 21 measured parameters of allergic airway 
disease presented in previous figures that compare CBA-treated groups to HDM plus DMSO group. Post hoc P values in the table are for parameters 
that were significantly different from HDM plus DMSO groups. ns, not significant compared with HDM plus PBS; nd, not determined because of 
noncompliant COD values.
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and TGR5 independent that occurs in tissue from organs that are nontraditional targets of  bile acids, 
including both cardiomyocytes and airway epithelial cells (50–52). The relative expression of  FXR in 
the lungs is also 2 log scales less than in traditional bile acid target tissues, such as the liver, kidneys, 
and intestines (53). In addition, there are 2 FXR genes, FXRα and FXRβ, with 4 isoforms of  FXRα that 
are differentially expressed based on tissue type (54). Little is known about the activity of  each FXRα 
isoform and its expression in the lungs. In contrast with FXR, TGR5 is encoded by a single exon and is 
highly expressed by several organs, including the lungs (55, 56). However, airway epithelial cells grown 
on an air-liquid interface and stimulated with the TGR5 agonist, INT-777, on the apical and basolateral 
sides of  the cell membrane revealed that TGR5 is preferentially expressed on the basolateral surface 
(52). Because the CBAs in the present study were administered oropharyngeally, TGR5 would not be 
accessible unless tight junctions between cells were compromised. Finally, different bile acids can act 
as agonists or antagonists of  FXR and TGR5, and they also have different affinities for each receptor 
(33). Thus, the inability of  TUDCA, AβM, INT-747, and INT-777 to activate downstream FXR and 
TGR5 signaling could be due to the limited expression of  FXR in the lungs, the specific FXRα isoforms 
expressed, the inaccessibility of  the TGR5 receptor to CBAs present in the airway lumen, or their low 
affinity for both receptors.
We hypothesized that TUDCA and AβM may be inhibiting allergen-induced UPR in allergic airway 
disease and thus decreasing allergen-induced inflammatory response. To address this hypothesis, we began 
by immunoprecipitating transducers of  the UPR from lysates prepared from the lungs of  CBA-treated 
mice. We conducted a bile acid assay on the samples and recovered more CBAs from samples in which 
ATF6α was immunoprecipitated compared with IRE1α and PERK, suggesting that CBAs may inhibit the 
UPR and allergic airway responses via direct interaction with the UPR transducers ATF6α and IRE1α. 
Interestingly, because latent ATF6α is found as a trimer on the ER membrane (42, 57), we speculate that 
this ATF6α trimer may be a preferred target for TUDCA and AβM binding as compared with PERK or 
IRE1α, which appear as monomers in their latent forms (57).
As a regulator of  the UPR, ATF6α activation can be both protective and detrimental to disease patho-
genesis (38, 58–61). Activated ATF6α acts as a transcription factor, regulating expression of  PDIs, chap-
erones, and antioxidants that aid in the proper folding of  proteins, thus reducing ER stress (9, 10). Alter-
natively, inhibition of  the ATF6α arm of  the UPR has led to reduced inflammation in an experimental 
autoimmune encephalomyelitis model of  multiple sclerosis (58).
The literature also suggests that the UPR via the IRE1/XBP1 axis or via ATF6α affects the epithelial 
cell responses to allergens or IL-13 stimulation, respectively (62). Similarly, ATF6α is known to regulate 
allergen-induced macrophage and airway smooth muscle responses (63–65). These studies indicate that 
many cell types and facets of  allergic asthma are influenced by various pathways of  UPR, including ATF6α.
Figure 6. TUDCA does not activate the FXR or TGR5 pathways in an allergen-induced model of asthma. (A) Illustration of mediators regulated down-
stream of canonical bile acid receptors FXR and TGR5. (B) Gene expression quantified by RT-qPCR from the lungs. One-way ANOVA, Tukey’s post hoc test. 
*P < 0.05 vs. PBS; #P < 0.05 vs. HDM plus PBS mice. n = 6–10 mice/group from 2 experiments (outliers removed, Nr0b2 in HDM plus TUDCA, n = 1). HK, 
housekeeping; ns, not significant. Error bars represent ± SEM.
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Interestingly, in a study of  diabetic mice, the impact of  TUDCA on disease pathogenesis was contin-
gent upon the presence of  ATF6α and lost in mice with pancreatic β cell–specific deletion of  ATF6α (66). 
Although at this juncture, we have not confirmed the need for ATF6α in CBA-mediated diminished allergic 
airway responses, we believe that future experiments with lung-specific ATF6α-knockout mice along with 
CBA treatment should provide insight into the involvement of  ATF6α.
Finally, our analysis of  ATF6α-dependent and -related genes both upstream and downstream of  ATF6α 
(38–42) showed increased expression and correlated with features of  asthma, including poor bronchodila-
tor response and blood eosinophilia.
Collectively, our work indicates that human patients with asthma and a murine model of  aller-
gic airway disease exhibit upregulation of  ATF6α-dependent genes. CBAs such as AβM and TUDCA 
potently resolve experimental allergic airway disease via the inhibition of  the allergen-induced UPR, by 
attenuating the UPR transducer ATF6α.
Methods
Mouse models of  HDM-induced allergic airway disease. All mice involved in allergy experiments were anesthe-
tized using isoflurane and exposed to the allergen HDM (item XPB70D3A2.5, lot 279020, normalized to 
protein content, GREER) suspended in PBS. Mice were administered 25 μg of  HDM via the nasopharyn-
geal route on day 1 and boosted on day 8. Mice were then administered 25 μg of  HDM consecutively on 
days 15 to 19, and days 25 and 27, before being analyzed on day 28 (Figure 1A and Figure 3B). All mice 
were females, BALB/cJ strain, from The Jackson Laboratory.
Human subjects. Airway epithelial brushings from patients with physician-diagnosed asthma and from 
subjects without asthma were obtained from the Department of  Medicine of  the UCSF. Airway epithelial 
Figure 7. CBAs do not activate the FXR or TGR5 pathways in an allergen-induced model of asthma. (A–G) Gene expression quantified by RT-qPCR from 
the lungs. One-way ANOVA, Tukey’s post hoc test. *P < 0.05 vs. DMSO plus PBS mice; #P < 0.05 vs. DMSO plus HDM mice. n = 6–10 mice/group from 2 
experiments (outliers removed, Nr0b2 in HDM plus AβM; Abcc2 in HDM plus AβM and HDM plus GnβM; Abcb4 in HDM plus TCCA and HDM plus AβM; Dio2 
in HDM plus ABM and HDM plus GnBM; Gpbar1 in HDM plus AβM; n = 1 outlier each). HK, housekeeping; ns, not significant. Error bars represent ± SEM.
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brushings from 10 nonasthmatic (healthy) subjects and 20 asthmatic patients were from the UCSF Airway 
Tissue Bank (Supplemental Table 1). All subjects were from a single clinical study (8) and represented a 
subset with enough remaining RNA quantity for quantitative PCR. 
CBAs. CBAs TCCA, GβM, AβM, and GnβM, along with a UBA, βM, were synthesized and purified 
in house as previously described (30, 31). TUDCA was purchased from Calbiochem (catalog 580549).
Solubility and treatment of  CBAs. All CBAs/UBA (TCCA, βM, GβM, AβM, and GnβM) with the excep-
tion of  TUDCA were dissolved in 0.5% DMSO in PBS (pH 7.2), while TUDCA was dissolved in PBS (pH 
7.2). Treatment groups received CBAs (0.75 mg/kg body weight) via the oropharyngeal route (intratracheal) 
on days 20, 22, 24, 26, and 28 (Figure 1A and Figure 3B), and the mice were euthanized 24 hours following 
the last treatment. The PBS (negative) and HDM (positive) control groups received 0.5% DMSO in PBS (pH 
7.2) as the vehicle at all time points (or PBS as the vehicle in experiments involving TUDCA). Administra-
tion of  CBAs (0.75 mg/kg) and 0.5% DMSO in PBS did not result in any visible distress or mortality.
An additional mouse experiment was conducted to exclude the FXR and TGR5 pathways as the mech-
anism through which the CBAs attenuate ER stress and allergic airway responses. In this experiment, 
Figure 8. Solitary administration of bile acid-specific agonists and CBAs does not activate the FXR or TGR5 pathways in the lungs. (A) Bile acid and 
vehicle treatment regimen. (B) Gene expression quantified by RT-qPCR from the lungs of mice 24 hours after administration of TUDCA, AβM, INT-747, and 
INT-777 (or DMSO vehicle control). n = 5 mice per group from 1 experiment. (C) Western blot analysis for phospho-PKA (p-PKA). (D) Densitometry for Western 
blot in C. Data were analyzed by 1-way ANOVA with Tukey’s post hoc test. *P < 0.05 vs. DMSO control group; ns, not significant vs. DMSO control group 
(Nr1h4 in TUDCA and HDM plus AβM; Dio2 in TUDCA, AβM, and INT-747; n = 1 outlier each). HK, housekeeping; ns, not significant. Error bars represent ± SEM.
 
1 3insight.jci.org   https://doi.org/10.1172/jci.insight.98101
R E S E A R C H  A R T I C L E
BALB/cJ mice were administered TUDCA, AβM, INT-747, or INT-777 (or DMSO/PBS as a vehicle 
control) via oropharyngeal instillation at 0.75 mg/kg. All mice, including TUDCA-treated mice in this 
experiment, received the 0.5% DMSO in PBS vehicle control. Mice were euthanized and lungs were ana-
lyzed 24 hours after administration.
Assessment of  AHR. Mice were anesthetized by the administration of  sodium pentobarbital (90 
mg/kg, intraperitoneal), followed by an injection of  the paralyzing agent pancuronium bromide. Mice 
were tracheotomized using an 18-gauge cannula and mechanically ventilated at 200 breaths/min using 
Figure 9. CBAs inhibit the UPR and airway inflammation via direct binding of the UPR transducer ATF6α. (A) Outline of the IP and subsequent bile 
acid assay protocol. (B) Bile acid assay performed on ATF6α, PERK, and IRE1α IP from HBE cells stimulated with or without TUDCA. One-way ANOVA, 
Tukey’s post hoc test. *P < 0.05; n = 3 samples per group from 1 experiment. (C and D) Bile acid assay performed on ATF6α and IRE1α IP from lung lysates 
of untreated and CBA/UBA–treated mice challenged with HDM. One-way ANOVA, Tukey’s post hoc test. #P < 0.05 vs. both PBS and HDM control groups; 
n = 4 mice per group from 2 experiments. (E) Representative Western blots from IPs of ATF6α and IRE1α from mouse lung lysates. (F) IP and subsequent 
bile acid assay from cell lysates of untreated and TUDCA/AβM–treated cells challenged with Tm. One-way ANOVA, Tukey’s post hoc test. *P < 0.05; n = 3 
samples per group from 1 experiment. (G) Western blots for UPR markers from cell lysates of untreated and TUDCA/AβM–treated cells challenged with Tm. 
IP, immunoprecipitation; UBA, unconjugated bile acid; CBA, conjugated bile acid; Ab, antibody; 3α-HSD, 3α-hydroxysteroid dehydrogenase; Red, reduced; 
Ox, Oxidized; ns, not significant. Error bars represent ± SEM.
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a FlexiVent computer-controlled, small-animal ventilator (SCIREQ). AHR measurements: Newtonian 
resistance (Rn), tissue damping (G), and tissue elastance (H) were measured from mice exposed to 
increasing concentrations of  aerosolized methacholine. AHR values for each dose are the average of  
3 adjacent measurements representing the peak response with a corresponding COD value of  greater 
than or equal to 0.89 obtained at incremental methacholine doses for each animal. AHR values at the 
saline dose were then set to 100% for each mouse, and all other values for that mouse were normalized 
to the saline dose. The COD reflects the quality of  the fit to the constant phase model. Outliers were 
removed using a cutoff  of  Q = 1% in the GraphPad Prism 7 program using the robust regression and 
outlier removal (ROUT) method.
Figure 10. UPR-related genes are upregulated in the airways of human patients with asthma. (A) RT-qPCR analysis of ATF6α-related genes from 
lung tissue. n = 10 healthy and n = 20 asthmatic subjects. Mann-Whitney U test, P values versus healthy subjects. (B and C) Correlation plot of 
the relative expressions of PDIA5 and RABAC1 to blood eosinophils and bronchodilator response (measured as change in absolute FEV1 relative 
to baseline). Spearman’s rank correlation coefficient (rs) of the group with asthma (healthy subjects excluded). P < 0.05 is considered significant. 
Error bars represent ± SD.
 
Table 3. Genes and correlation with clinical variables
Gene Clinical variable Spearman’s Rho P value n
PDIA5 PC20 –0.52521 0.017409 20
RABAC1 PC20 –0.56584 0.009309 20
COPE FEV1/FVC –0.50677 0.0241404 20
CREB3 Blood eosinophils 0.464259 0.039195 20
ORMDL3 PC20 –0.49737 0.025662 20
TXN % FEV1 –0.48757 0.029209 20
TXN FEV1/FVC –0.55338 0.012645 20
ERP44 3-genemean –0.46917 0.038443 20
XBP1 FeNO –0.56786 0.029804 15
XBP1 3-genemean –0.63459 0.003297 20
Expression of ER stress–related genes correlates with clinical features of asthma. Spearman’s rank correlation coefficient (rs) of the relative expression of 
ER stress–related genes to clinical features of asthma from patients with asthma only. P < 0.05 is considered significant. 3-genemean, mean of standardized 
relative normalized log2 expression of periostin, CLCA1, and SERPINB2 by RT-qPCR; PC20, concentration of methacholine causing a 20% drop in FEV1; FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity; FeNO, fraction of exhaled nitric oxide.
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Bronchoalveolar lavage fluid processing. Bronchoalveolar lavage fluid (BALF) was collected by washing 
lungs with 1 ml of  sterile PBS. Total and differential cell counts were performed as previously described (6). 
Briefly, cells were separated by centrifugation, and red blood cells were lysed before counting total cells. 
Differential cell counts were obtained via cytospins using Hema3 stain reagents (Thermo Fisher Scientific). 
Differentials were performed on a minimum of  300 cells.
ELISA. Right lung lobes were flash frozen, pulverized, and lysed in buffer containing 137 mM Tris-HCl 
(pH 8.0), 130 mM NaCl, and 1% NP-40. Samples were normalized to total lung protein and assayed for 
IL-13, IL-17A, IL-4 (eBioscience), IL-6, CCL11 (eotaxin-1), CCL20 (MIP-3α) and CXCL1 (KC) (R&D 
Systems) by ELISA according to manufacturer’s instructions (Supplemental Table 2).
Western blot analysis. Right lung lobes were flash frozen, pulverized, and lysed in buffer containing 
137 mM Tris-HCl (pH 8.0), 130 mM NaCl, and 1% NP-40. Cultured HBE cells were directly lysed 
on the cell culture plates with the same buffer. Insoluble proteins were pelletized via centrifugation, 
and the supernatant was used for protein quantification. Furthermore, protein samples resuspended in 
loading buffer with dithiothreitol were resolved by SDS-PAGE. Proteins were transferred to PVDF and 
membranes were probed using a standard immunoblotting protocol. The primary antibodies recognizing 
PDIA3 and GRP94 were purchased from Enzo Life Sciences, CHOP was from Novus Bio, and GRP78, 
ATF6α50, and PDIA6 were from Abcam. PDIA5 was from Novus Bio, and GAPDH was from Bio-
Legend. Details of  the antibodies are provided in Supplemental Table 3. The quantification of  protein 
expression was performed by densitometry using ImageJ software (NIH, https://imagej.nih.gov/ij/). 
See complete unedited blots in the supplemental material.
Analysis of  mRNA expression. Expression levels of  Muc5ac, Clca1, Gpbar1, Nr1h4, Abcb4, Abcc2, Nr0b2, 
Nos3, and Dio2 were quantified from mouse lungs. Flash-frozen right lung lobes were pulverized, and total 
RNA was extracted using Qiazol (Qiagen). RNA was purified using the RNeasy kit (Qiagen). We reverse 
transcribed 1 μg of  RNA to cDNA (Promega), for quantification of  mRNA expression using SYBR Green 
Supermix (Bio-Rad). Expression values were normalized to the geometric mean of  3 housekeeping genes 
(Gapdh, Pp1, and Rp2) using the ΔΔCT method. The primers used in this study are listed in Supplemen-
tal Table 4. Transcripts prepared from human airway brushings were analyzed by 2-step, nested-primer 
RT-qPCR (Supplemental Table 5) as previously described (8, 36, 37). Data were normalized to the mean of  
GAPDH, PPIA, and RPL37A as previously described (36, 37).
Quantification of  mucus metaplasia. The tissue sections (5 μm) from paraffin blocks of  lung were mounted 
on slides, and mucus metaplasia was assessed by PAS. The images were captured using an Olympus BX50 
light microscope, and mucus metaplasia was measured by quantifying the percentage of  positively PAS-
stained area of  airways, using MetaMorph software as described previously (7). Muc5ac and Clca1 mRNA 
expression were assessed via real-time RT-qPCR analysis.
Cell culture experiments. The HBE cell line was purchased from ATCC (catalog CRL4051) and cultured as 
previously described (5). HBE cells used in the bile acid assay were treated with 750 μM of TUDCA or AβM 
(or PBS as a vehicle control) and harvested after 1 hour using ice-cold PBS, and the cell lysates were centri-
fuged at 9,400 g for 10 minutes at 4°C. The protein concentration of  supernatant samples was quantified.
Immunoprecipitation and the bile acid assay. Cell lysates from cultured HBE cells treated with or with-
out TUDCA were subjected to immunoprecipitation. ATF6α, IRE1α, and PERK were immunoprecipi-
tated using primary antibodies (ATF6α and IRE1α from Abcam, PERK from Cell Signaling Technology). 
ATF6α alone was immunoprecipitated from the lung lysates of  mice treated with or without TUDCA/
AβM. The Protein G Agarose beads (Invitrogen, 15920-010) containing immunoprecipitates were gently 
washed using lysis buffer (137 mM Tris-HCl, pH 7.0, and 130 mM NaCl) without the detergent (3 times) to 
remove the unbound CBAs, and the bile acid assay was performed to evaluate the binding capacity of  bile 
acids to ATF6α, PERK, and IRE1α. Total Bile acid assay kit (catalog STA-631) was purchased from Cell 
Biolabs Inc., and the assay was performed as per the manufacturer’s instructions with slight modifications, 
including Protein G Agarose beads as controls.
Statistics. Human data were analyzed as described in the figure and table legends. All mouse data were 
analyzed as follows: The ROUT method was first used to identify outliers in GraphPad Prism 7 with a cutoff  
of  Q = 1%, and they were removed from analysis. The Shapiro-Wilk normality test was applied, and wherever 
1 or more groups did not pass the normality test, the Kruskal-Wallis (nonparametric) test, followed by the 
2-stage linear step-up procedure of  Benjamini, Krieger, and Yekutieli, were performed to control for the false 
discovery rate (FDR). Wherever the data passed the normality test, 1-way analysis of  variance (ANOVA) was 
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performed, and Tukey’s post hoc test was applied to adjust for multiple comparisons. Two-tailed Student’s t 
test was used. The specific statistical analyses used are mentioned in the figure legends. Data were averaged 
and expressed as the mean ±SEM. The FDR or Tukey’s adjusted P value of  less than 0.05 were considered 
to be statistically significant.
Study approval. All mice were housed, maintained, and used in the experiments as approved by the 
Institutional Animal Care and Use Committee of  the University of  Vermont (protocol no. 15-009). The 
study (NCT00595153) was approved by the UCSF Committee on Human Research, written informed 
consent was obtained from all subjects, and all studies were performed in accordance with the principles 
expressed in the Declaration of  Helsinki. The Institutional Review Board of  the UCSF approved the provi-
sion of  data from de-identified patients for presentation in this manuscript.
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